1Y Target$100.06Near-term target
5Y Target$123.99Compound horizon
10Y Target$158.26Long-dated conviction
FCF$137mTTM · 03/26CFCF $137m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+21.2%TTM YoYA-Revenue +21.2% — strong growth, well above S&P median (~7%) · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.12totalA-D/E 0.12 — conservative leverage, strong balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/E17.3xB+P/E 17.3 — at or below S&P median, reasonable
PEG0.82proxyB+PEG 0.82 — near fair value, classic Lynch benchmark (1.0) · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Health Care · market cap $1.7b. Down 26% from 52-week high of $124.44 — deep drawdown territory. Revenue growing +21%, comfortably above the S&P median. PEG 0.82 — paying under fair value for the growth rate.
Moat
Moat signals from the quantitative card are modest — profitability and capital efficiency are middle-of-pack. The thesis here depends on softer factors (switching costs, brand, distribution, regulatory protection) not captured by the 7-grade screen.
Risk
Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon
1-3 yr $100.06 (structural (no analyst coverage)) — multiple re-rating thesis requires a catalyst. 5 yr $123.99 at ~6% CAGR — dividend + buyback compounding. 10 yr $158.26 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.